German pharma rebates fund health insurer surplus, but drug spending rises again
This article was originally published in Scrip
Executive Summary
German health insurers enjoyed a €4 billion surplus in 2011, fuelled partly by a 4% drop in drug spending, which was in turn driven by increased mandatory rebates and a price freeze introduced in 2010. Although drug spending in Germany appears to be rising again, pharmaceutical companies will be calling for the government to reduce rebates to previous levels, says the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE).
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.